Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Arbitration Ruling!!!

<< Previous

Bullboard Posts

Next >>

Comment by pabalooon Jan 14, 2021 9:03am

141 Views

Post# 32292717

RE:RE:Arbitration Ruling!!!

Just going by the last conference call and the reply from Mr. Mull:
Bausch and the arbitration that we're having with them. We are going through the process. We expect that the arbitrator will make a decision no later than the end of January of 2021, and unless the matter is settled between the parties before that. -----

<< Previous

Bullboard Posts

Next >>

Canopy Growth nears adjusted EBITDA profitability in Q2 2025